These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16626409)

  • 1. Determinants of health economic decisions in actual practice: the role of behavioral economics. Summary of the presentation given by Professor Daniel Kahneman at the ISPOR 10th Annual International Meeting First Plenary Session, May 16, 2005, Washington, DC, USA.
    Value Health; 2006; 9(2):65-7. PubMed ID: 16626409
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of quality-adjusted life-years in cost-effectiveness studies.
    Sculpher M
    Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
    [No Abstract]   [Full Text] [Related]  

  • 3. Health economics--what the nephrologist should know.
    Palmer AJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1038-41. PubMed ID: 15840678
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons for health care from behavioral economics.
    Natl Bur Econ Res Bull Aging Health; 2008; (4):1-2. PubMed ID: 19340980
    [No Abstract]   [Full Text] [Related]  

  • 5. Money matters: what to look for in an economic analysis.
    Dijksman LM; Poolman RW; Bhandari M; Goeree R; Tarride JE;
    Acta Orthop; 2008 Feb; 79(1):1-11. PubMed ID: 18283565
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations for economic evaluations of non-pharmacological arthritis care: results from the CARE VI meeting 2010.
    van den Hout WB; Bremander A; Vliet Vlieland TP
    Musculoskeletal Care; 2011 Jun; 9(2):120-3. PubMed ID: 21365738
    [No Abstract]   [Full Text] [Related]  

  • 7. Handling uncertainty when performing economic evaluation of healthcare interventions.
    Briggs AH; Gray AM
    Health Technol Assess; 1999; 3(2):1-134. PubMed ID: 10448202
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics. Measuring subjective well-being.
    Layard R
    Science; 2010 Jan; 327(5965):534-5. PubMed ID: 20110492
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterizing preferences for health outcomes in economic evaluations.
    Tosteson AN
    J Rheumatol Suppl; 2003 Dec; 68():15-8. PubMed ID: 14725249
    [No Abstract]   [Full Text] [Related]  

  • 11. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus.
    Graf von der Schulenburg JM; Greiner W; Jost F; Klusen N; Kubin M; Leidl R; Mittendorf T; Rebscher H; Schoeffski O; Vauth C; Volmer T; Wahler S; Wasem J; Weber C;
    Value Health; 2008; 11(4):539-44. PubMed ID: 18194408
    [No Abstract]   [Full Text] [Related]  

  • 12. Health outcomes in economic evaluation: who should value health?
    Stamuli E
    Br Med Bull; 2011; 97():197-210. PubMed ID: 21285110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methods for cost-effectiveness evaluation of intensive care].
    Heslet L; Andersen JS; Keiding H
    Ugeskr Laeger; 2007 Feb; 169(8):721-4. PubMed ID: 17313927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of clinical effects.
    Teerawattananon Y; Thavorncharoensap M; Mohara A
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S38-42. PubMed ID: 19253486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What affects the quality of economic analysis for life-saving investments?
    Hahn RW; Kosec K; Neumann PJ; Wallsten S
    Risk Anal; 2006 Jun; 26(3):641-55. PubMed ID: 16834624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?
    Mansley EC; Elbasha EH
    Health Econ; 2003 Mar; 12(3):187-98. PubMed ID: 12605464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology.
    Boonen A; Maetzel A; Drummond M; Suarez-Almazor M; Harrison M; Welch V; Tugwell PS
    J Rheumatol; 2009 Sep; 36(9):2045-9. PubMed ID: 19738211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presentation of economic evaluation results.
    Chaikledkaew U; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S66-73. PubMed ID: 19253489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.